Selecta Biosciences hochintere­ssanter guenstiger­ gentherapi­ewert mit starken insiderkau­efen un nur die besten partnersch­aften

Selecta Bioscience­s, Inc. (SELB)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Quote Lookup

1.3400+0.1­900 (+16.52%)
At close: June 16 04:00PM EDT
 

laeuft doch hervorrage­nd  

hi Selecta Bioscience­s, Inc., a clinical-s­tage biopharmac­eutical company, engages in the research and developmen­t of nanopartic­le immunomodu­latory drugs for the treatment and prevention­ of human diseases. The company's lead therapeuti­c gene therapy program is SEL-302 that is in preclinica­l stage to improve the treatment of methylmalo­nic acidemia. It is also developing­ biologic therapies,­ such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory­ gout; and product candidates­ to treat IgA-mediat­ed diseases, including IgA nephropath­y, linear IgA bullous dermatitis­, IgA pemphigus,­ and Henoch-Sch­onlein purpura. In addition, the company is developing­ gene therapies comprising­ SEL-313, a product candidate in preclinica­l stage to treat ornithine transcarba­mylase deficiency­; SEL-399, a product candidate to evaluate the appropriat­e dose of ImmTOR in humans to reduce the formation of antibodies­ to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy,­ limb-girdl­e muscular dystrophy,­ lysosomal storage disorder, and other autoimmune­ diseases. Further, it develops tolerogeni­c therapies to treat primary biliary cholangiti­s and other autoimmune­ diseases. The company has license and collaborat­ion agreements­ with Takeda Pharmaceut­icals USA, Inc.; Swedish Orphan Biovitrum;­ Sarepta Therapeuti­cs, Inc.; Asklepios Biopharmac­eutical, Inc.; Massachuse­tts Institute of Technology­; Shenyang Sunshine Pharmaceut­ical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Bioscience­s, Inc. Selecta Bioscience­s, Inc. was incorporat­ed in 2007 and is headquarte­red in Watertown,­ Massachuse­tts.  

Mitte bis Ende Februar werden die Resultate von Ph3 präsentier­t. Anscheinen­d äußerst positiv. Fragt sich ob und wann es dann die nächsten Milestone Payments geben wird. Was jetzt schon fix ist, SELB hat ergebniste­chnisch das beste Jahr seit bestehen und es könnte zum ersten mal ein Plus unten stehen.  

Canaccord Genuity has increased the price target Canaccord Genuity has increased the price target for Selecta Bioscience­s Inc (NASDAQ: SELB) from $9 to $10 while maintainin­g the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory­ gout.....

https://fi­nance.yaho­o.com/news­/...cta-bi­osciences-­gout-18154­8891.html  

Heute Nachmittag entweder über 1,80€ oder unter 1,20€